NVNO
enVVeno Medical Corporation
There isn't enough reported data to score NVNO yet.
NVNO Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
NVNO's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
NVNO PE Valuation
NVNO has no meaningful PE right now: it lost money over the past year.
NVNO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| High |
Analysts expect NVNO's losses to shrink, with revenue growing.
NVNO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$23.32 | +$14.48 |
| Q2 2026 | -$25.08 | +$16.92 |
| Q1 2026 | -$31.26 | +$10.04 |
| Q4 2025 | -$33.07 | +$11.38 |
| Q3 2025 | -$37.80 | +$7.00 |
| Q2 2025 | -$42.00 | +$6.30 |
| Q1 2025 | -$41.30 | +$16.45 |
| Q4 2024 | -$44.45 | +$22.40 |
NVNO is still losing money, but far less than before: $23.32 per share over the past year, against $420.00 at its worst in late 2019.
NVNO Quarterly Revenue
NVNO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | -$3.4M | +$1.7M |
| Q3 2025 | -$4.4M | -$107K |
| Q4 2024 | -$5.1M | -$132K |
| Q3 2024 | -$4.3M | -$69K |
| Q2 2024 | -$3.9M | +$662K |
| Q1 2024 | -$3.6M | +$1.6M |
| Q4 2023 | -$5M | -$1.1M |
| Q3 2023 | -$4.2M | +$281K |
NVNO has burned cash in almost every quarter: −$16M over the past year, against −$17M the year before.
NVNO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.4% | +23K shares |
| 1 year | +21% | +118K shares |
| 3 years | +116% | +373K shares |
| 5 years | +185% | +451K shares |
| Available history | +3753% | +676K shares |
NVNO has 694,000 diluted shares, up 21% from a year ago.
NVNO Net Leverage
NVNO's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NVNO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 30.5 | Neutral |
| Stochastic | 5.4 | Oversold |
NVNO's weekly RSI is 31 (neutral) and its Stochastic is 5 (oversold).
NVNO PE vs Healthcare Sector
NVNO has no meaningful PE right now: it lost money over the past year.
NVNO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $7.46 | 12% below |
| 20 week MA | $9.37 | 30% below |
| 50 week MA | $10.5 | 37% below |
| 100 week MA | $53.1 | 88% below |
| 200 week MA | $108.7 | 94% below |
NVNO is in a downtrend: it's below all five of its weekly moving averages, and 94% below its 200-week average.
NVNO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $426.3 | $281.8 | -34% |
| 2021 | $281.8 | $241.2 | -14% |
| 2022 | $241.2 | $161.4 | -33% |
| 2023 | $161.4 | $182.7 | +13% |
| 2024 | $182.7 | $112.0 | -39% |
| 2025 | $112.0 | $12.8 | -89% |
| 2026 YTD | $12.8 | $6.58 | -49% |
NVNO has finished lower in five of the last six years. It's down 49% so far in 2026.